An observational study in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Saudi Arabia. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2016-10-28.
Sponsored by Novo Nordisk A/S · Observational
This study is conducted in Asia. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using insulin detemir under normal clinical practice conditions in the Gulf countries
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 747 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 102 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Type 2 diabetic patients
Exclusion Criteria:
Drug: insulin detemir
Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Also known as: Levemir®, NN304
Incidence of serious adverse drug reactions, evaluated via number of major hypoglycaemic events
Time frame: For the duration of the study (32 weeks)
Number of serious adverse events
Time frame: For the duration of the study
Number of all adverse events
Time frame: For the duration of the study
Number of all - daytime and nocturnal - hypoglycaemic events
Time frame: In the 4 weeks before baseline compared to 4 weeks before interim and final visits
Weight changes compared to baseline
Time frame: At the end of the study
HbA1c compared to baseline
Time frame: At the end of the study
Fasting glucose level control compared to baseline as measured by FBG
Time frame: After 16 and 32 weeks of treatment
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S